등록자료 카탈로그

자동 수집 등록자료가 포함된 탐색용 목록입니다. 약물별 상세 해설 검토가 끝난 목록과 구분하며 이 목록 화면은 검색 색인 대상에서 제외합니다. 등록 단계·시험 수는 효능 또는 경쟁력의 판정이 아닙니다.

trastuzumab (Herceptin, Ado-trastuzumab, Ado-trastuzumab (T) emtansine (T-DM1))

Ofatumumab (Ofatumumab)

cadonilimab (cadonilimab)

Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1))

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Golimumab (Golimumab)

Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin)

Ivonescimab (Ivonescimab)

Relatlimab (Relatlimab)

belantamab mafodotin (Blenrep, GSK2857916)

Tiragolumab (Tiragolumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

SHR-A1811 (SHR-A1811)

sac-TMT (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (sac-TMT))

high dose (ZM-02, ZM-02 (high dose))

T-DM1 (Ado-trastuzumab emtansine, Ado-trastuzumab emtansine (T-DM1))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))

등록자료 카탈로그

trastuzumab (Herceptin, Ado-trastuzumab, Ado-trastuzumab (T) emtansine (T-DM1))

Ofatumumab (Ofatumumab)

cadonilimab (cadonilimab)

Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1))

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Golimumab (Golimumab)

Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin)

Ivonescimab (Ivonescimab)

Relatlimab (Relatlimab)

belantamab mafodotin (Blenrep, GSK2857916)

Tiragolumab (Tiragolumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

SHR-A1811 (SHR-A1811)

sac-TMT (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (sac-TMT))

high dose (ZM-02, ZM-02 (high dose))

T-DM1 (Ado-trastuzumab emtansine, Ado-trastuzumab emtansine (T-DM1))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))

등록자료 카탈로그

trastuzumab (Herceptin, Ado-trastuzumab, Ado-trastuzumab (T) emtansine (T-DM1))

Ofatumumab (Ofatumumab)

cadonilimab (cadonilimab)

Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1))

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Golimumab (Golimumab)

Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin)

Ivonescimab (Ivonescimab)

Relatlimab (Relatlimab)

belantamab mafodotin (Blenrep, GSK2857916)

Tiragolumab (Tiragolumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

SHR-A1811 (SHR-A1811)

sac-TMT (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (sac-TMT))

high dose (ZM-02, ZM-02 (high dose))

T-DM1 (Ado-trastuzumab emtansine, Ado-trastuzumab emtansine (T-DM1))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))